Zelpultide alfa is under clinical development by Airway Therapeutics and currently in Phase I for Bronchopulmonary Dysplasia. According to GlobalData, Phase I drugs for Bronchopulmonary Dysplasia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Zelpultide alfa LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zelpultide alfa overview
AT-100 is under development for the treatment of bronchopulmonary dysplasia (BPD), influenza, respiratory syncytial virus (RSV), coronavirus disease 2019 (COVID-19), cystic fibrosis and other inflammatory diseases. It is administered through intratracheal route. It is a recombinant human surfactant protein D (rhSP-D). SP-D is required for the normal structure and function of lung surfactant. It is a protein replacement therapy.
Airway Therapeutics overview
Airway Therapeutics, formerly Airway Therapeutics, is a biotechnology company. It develops therapeutics and biologics for life-threatening respiratory and inflammatory diseases. The company’s product pipeline includes rhSP-D, a novel recombinant human protein that modulates immune response and reduces inflammation and infection: and AT-100, a biologic novel recombinant that treats bronchopulmonary dysplasia (BPD) which affects preterm infant lungs. Its products are also used to treat influenzas, respiratory syncytial virus, COVID-19, and other respiratory, non-respiratory and anti-inflammatory diseases. Airway Therapeutics is headquartered in Marietta, Georgia, the US.
For a complete picture of Zelpultide alfa’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
